6 Largest Psychedelic Drug Stocks Were -20% In December

The munKNEE Psychedelic Drug Stocks Index tracks the six (6) largest psychedelic stocks, by market capitalization, that research the treatment of mental illnesses based on the use of one or more of ten (10) different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them). Below are their performances in December and for all of 2022:

  1. Mind Medicine (MNMD): DOWN 13.8% in December; DOWN 89.5% in 2022 
    • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
  2. GH Research (GHRS): DOWN 15.1% in December; DOWN 59.1% in 2022
    • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
  3. Seelos (SEEL): DOWN 20.7% in December; DOWN 60.1% in 2022 
    • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
  4. Cybin (CYBN): DOWN 21.6% in December; DOWN 75.8% in 2022
    • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
  5. Compass Pathways (CMPS): DOWN 24.2% in December; DOWN 64.7% in 2022
    • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
  6. Atai (ATAI): DOWN 26.9% in December; DOWN 66.2% in 2022
    • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.

In total, the Index went DOWN 20.0% in December, and DOWN 60.2% in 2022.

Six (6) other psychedelic companies (see details here) are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, substance abuse withdrawal, and depression. All are highly speculative investments and penny stocks with tiny market capitalization. They are as follows, in alphabetical order:

  1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF);
  2. Delic Corp. (CSE: DELC|OTCQB: DELCF);
  3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF);
  4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF);
  5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF);
  6.  Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)

The above psychedelic-assisted therapy clinic stocks went DOWN 22.7%, on average, in December and went DOWN 81.5% in all of 2022.


More By This Author:

Conservative Cannabis Stocks Index Only -3% In 2022
The Ancillary Cannabis Stocks Index Collapsed 64% In 2022
The 12 Largest American Cannabis MSOs Collapsed 73% In 2022

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.